



Worldwide distributed by www.adipogen.com



# PRODUCT DATA SHEET

**Page** 1/3

# **ODN 1826 (Type B) Endotoxin-free (sterile)**

Cat. No.: IAX-200-002 Lot. No.:

Sequence	5'-tccatga <b>cg</b> ttcctga <b>cg</b> tt-3' (lower case letters: phosphorothioate linkage: nuclease resistant)
Synonyms	CpG ODN TLR9 Agonist: B Type (species: rodent)
MW	6,383 g/mol
Formulation	Lyophilised. Sterile. 100µg size includes 1.5ml ddWater Endotoxin-free (sterile) (Cat. No.: IAX-900-002-LD15). Img and 3x1mg sizes each include 10ml ddWater Endotoxin-free (sterile) (Cat. No.: IAX-900-002-L010).
Endotoxin-free	Bacterial Endotoxin Test (kinetic turbidimetric LAL method) according to Ph. Eur. 9. Passed according to specification: Endotoxin-free: <0.002 EU/µg.
Sterility	Filter method: according to Ph. Eur. 9. Passed according to specification:  No growth in Thioglycolate medium at 30-35°C after 14 days.  No growth in Soybean Casein Digest Broth (TSB) at 20-25°C after 14 days.
Handling	Keep sterile. Reconstitution: Dissolve total vial content in sterile endotoxin-free water or PBS. Add 50% of solvent and let dissolve for 10mins. Add remaining 50% of the solvent and mix thoroughly Moderate warming may aid dissolving.
Activity	Optimal concentration is dependent upon cell type, species, desired activation and analysis: in vitro 0.1-1 µM (~0.6-6.0 µg/ml); in vivo 50-250 µg in rodent animal models.  Negative control: GpC ODN 2138 (Cat. No.: IAX-200-201). As an alternative control without agonistic nor antagonistic activity consider CTRL2-ODN (Cat. No.: IAX-200-208).
Shipping	Ambient
Storage	2-8°C. After reconstitution in water prepare aliquots, store between -15°C and -25°C (shelf-life: 6 months). Avoid freeze/thaw cycles. After thawing stable for one day at 2-8°C, and do not freeze again
Stability	2 years after receipt (unopened and as supplied)
MSDS	Available on request

**Document No.:** |AX-200-002 | **Version:** |.7 | **Issue Date:** 30/01/2023





### **PRODUCT DATA SHEET**

Page 2/3

### **ODN** 1826 (Type B) Endotoxin-free (sterile)

Cat. No.: IAX-200-002 Lot. No.:

### **Product Specific References**

General Information

- [1] In Situ Therapeutic Cancer Vaccination with an Oncolytic Virus Expressing Membrane-Tethered IL-2. Liu W, et al. Mol. Ther. Oncolytics (2020); 17:350
- [2] Small Molecule NF-kB Inhibitors as Immune Potentiators for Enhancement of Vaccine Adjuvants. Moser BA, et al. Front. in Immun. (2020); 11:511513
- [3] Multifactorial Design of a Supramolecular Peptide Anti-IL-17 Vaccine Toward the Treatment of Psoriasis Shores LS, et al. Front. in Immun. (2020); 11:1855
- [4] C-type lectin receptors Mcl and Mincle control development of multiple sclerosis-like neuroinflammation. N'diaye M, et al. J. Clin. Invest. (2020); 130:838
- [5] Increased vaccine tolerability and protection via NF-KB modulation. Moser BA, et al. Sci. Adv. (2020); 6: eaaz8700
- [6] Inflammatory Properties and Adjuvant Potential of Synthetic Glycolipids Homologous to Mycolate Esters of the Cell Wall of Mycobacterium tuberculosis. Tima HG, et al. J. Innate Immun. (2017); 9:162
- Unmethylated CG dinucleotides within particular sequence contexts are responsible for the immunostimulatory activity of bacterial DNA. Synthetic oligonucleotides (ODN) that contain such CpG motifs (CpG ODNs) mimic microbial DNA.
- The innate immune system of vertebrates has the ability to recognize CpG motifs in microbial DNA via the Toll-like receptor (TLR) 9 if the CpG ODN were free of additional immune stimulatory contaminants often present in synthetic commercial CpG ODN preparations designed for molecular biology applications (i.e. PCR). Given that high quality CpG ODNs were used [i.e. endotoxin-free], a close link has been established between the expression of TLR9 on certain immune cell subsets and the modulation of the immune system by CpG DNA.
- Different types of CpG ODNs were identified based on their differing biological effects on different cell types:
  - ODN Type A is a potent inducer of IFN-α in human PDC, (i.e. ODN 1585 or 2216) leading to antigen presenting cell (APC) maturation.
  - ODN **Type B** (i.e. ODN 2006 or ODN 1668/ODN 1826) is a weak inducer of IFN-α but rather stimulates production and increasing costimulatory and Ag-presenting molecules and triggers proliferation of B-cells, IgM, and IL-6 production.
  - A third type of CpG ODN has been identified, termed ODN Type C, with both high induction of INF-α in PDC and activation of B-cells. The sequence of CpG Type C (also called K) (i.e. ODN 2395 or M362) combines elements of both Type A and Type B and contain a central palindromic sequence with CG dinucleotides, a characteristic feature of Type A, and a 'TCGTCG' motif at the 5' end, present in Type B CpG ODNs.
- Although the CpG motifs are thought to differ between mice and humans, in both species the recognition of CpG ODNs is mediated by TLR9. The optimal CpG motif in humans is GTCGTT and GACGTT for the murine sequence. However, recent evidence suggests that this sequence specificity is restricted to phosphorothioate (PS)-modified ODN and is not observed when a natural phosphodiester backbone is used. In recent years sequence requirements, specificity, signalling pathways and kinetics of the TLR9 suppression by 'inhibitory ODNs' (iODNs) have been investigated.

**Document No.:** IAX-200-002 | **Version:** I.7 | **Issue Date:** 30/01/2023





### **PRODUCT DATA SHEET**

Page 3/3

## **ODN 1826 (Type B) Endotoxin-free (sterile)**

Cat. No.: IAX-200-002 Lot. No.:

#### References

- [1] Comparison of different CpG oligodeoxynucleotide classes for their capability to stimulate human NK cells. Sivori S, et al. Eur. J. Immunol. (2006); 36:961
- [2] Innate immune responses induced by classes of CpG oligodeoxynucleotides in ovine lymph node and blood mononuclear cells. Booth JS, et al. Vet. Immunol. Immunopathol. (2007); 115:24
- [3] Impact of class A, B and C CpG-oligodeoxynucleotides on in vitro activation of innate immune cells in human immunodeficiency virus-1 infected individuals. Martinson JA, et al. Immunology (2007); 120:526
- [4] Three CpG oligodeoxynucleotide classes differentially enhance antigen-specific humoral and cellular immune responses in mice. Liu Y, et al. Vaccine (2011); 29:5778
- [5] Toll-like receptor and IL-12 signaling control susceptibility to contact hypersensitivity. Martin SF, et al. J. Exp. Med. (2008); 205:21
- [6] DNA Motifs suppressing TLR9 responses. Trieu A, et al. Crit. Rev. Immunol. (2006); 26:527
- [7] Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. Barrat FJ, et al. J. Exp. Med. (2005); 202:1131
- [8] A TLR7 antagonist restricts interferon-dependent and -independent immunopathology in a mouse model of severe influenza. Rappe JCF, et al. J. Exp. Med. (2021); 218:e20201631

**Document No.:** IAX-200-002 | **Version:** I.7 | **Issue Date:** 30/01/2023

Access to this material must be restricted to personnel, who is appropriately experienced, qualified, competent and properly trained to use it. Material Safety Data Sheet is available upon request.

DISCLAIMER: THIS PRODUCT IS NOT INTENDED OR APPROVED FOR HUMAN, DIAGNOSTICS OR VETERINARY USE, USE OF THIS PRODUCT FOR HUMAN OR ANIMAL TESTING